Bullboard - Stock Discussion Forum Filament Health Corp N.FH

Alternate Symbol(s): FLHLF

Filament Health Corp. is a Canada-based clinical-stage natural psychedelic drug development company. The Company’s platform of intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. The Company’s first three botanical drug candidates are standardized, purified extracts of Psilocybe cubensis fruiting bodies include: PEX010 Psilocybin - oral... see more

Add To Watchlist

NEO:FH - Post Discussion

Filament Health Corp > FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT

View:

Post by Betteryear2 on Jun 30, 2023 8:09am

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT

NeoLumina's license for Filament's botanical psilocybin drug candidate provides exclusive global right to clinical and commercial development for eating disorders

VANCOUVER, BC, June 30, 2023 /CNW/ - Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) ("Filament" or the "Company"), a clinical-stage natural psychedelic drug development company, today announced an exclusive global licensing agreement with NeoLumina Bioscience Inc. ("NeoLumina"), a company focused on the development and commercialization of novel therapeutics inspired by psychedelics. Under the terms of the agreement, Filament will license its proprietary botanical psilocybin drug candidate, PEX010, and associated intellectual property, to NeoLumina for clinical and commercial development related to eating disorders. PEX010 is formulated as an oral capsule, and has both US Food and Drug Administration and Health Canada authorization to enter into phase 1 and phase 2 human clinical trials.

FILAMENT HEALTH ENTERS EXCLUSIVE LICENSING AGREEMENT WITH NEOLUMINA BIOSCIENCE INC. (newswire.ca)

283